279.07 USD
-0.84 (-0.3%)
279.07 USD
0 (0%)
CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 238 industry peers in the Capital Markets industry. CME has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, CME is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- CME had positive earnings in the past year.
- In the past year CME had a positive cash flow from operations.
- Each year in the past 5 years CME has been profitable.
- Each year in the past 5 years CME had a positive operating cash flow.
1.2 Ratios
- CME has a Return On Assets (1.99%) which is comparable to the rest of the industry.
- The Return On Equity of CME (13.18%) is better than 72.69% of its industry peers.
- CME has a Return On Invested Capital of 18.72%. This is amongst the best in the industry. CME outperforms 95.38% of its industry peers.
- CME had an Average Return On Invested Capital over the past 3 years of 15.81%. This is significantly above the industry average of 7.27%.
- The last Return On Invested Capital (18.72%) for CME is above the 3 year average (15.81%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROIC | 18.72% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
1.3 Margins
- CME has a better Profit Margin (32.91%) than 79.41% of its industry peers.
- CME's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 80.16%, CME belongs to the best of the industry, outperforming 98.74% of the companies in the same industry.
- CME's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A |
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for CME remains at a similar level compared to 1 year ago.
- The number of shares outstanding for CME has been increased compared to 5 years ago.
- Compared to 1 year ago, CME has an improved debt to assets ratio.
2.2 Solvency
- CME has a debt to FCF ratio of 0.84. This is a very positive value and a sign of high solvency as it would only need 0.84 years to pay back of all of its debts.
- CME's Debt to FCF ratio of 0.84 is amongst the best of the industry. CME outperforms 89.50% of its industry peers.
- CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
- CME's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CME outperforms 78.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CME has a Current Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of CME (1.02) is comparable to the rest of the industry.
- A Quick Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
- The Quick ratio of CME (1.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 8.41% over the past year.
- Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.57% on average per year.
- Looking at the last year, CME shows a quite strong growth in Revenue. The Revenue has grown by 10.03% in the last year.
- CME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.14% yearly.
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
3.2 Future
- CME is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.92% yearly.
- The Revenue is expected to grow by 4.71% on average over the next years.
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue Next Year6.53%
Revenue Next 2Y5.68%
Revenue Next 3Y5.64%
Revenue Next 5Y4.71%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.46, CME can be considered very expensive at the moment.
- CME's Price/Earnings ratio is a bit more expensive when compared to the industry. CME is more expensive than 68.07% of the companies in the same industry.
- When comparing the Price/Earnings ratio of CME to the average of the S&P500 Index (27.32), we can say CME is valued inline with the index average.
- The Price/Forward Earnings ratio is 23.70, which indicates a rather expensive current valuation of CME.
- Based on the Price/Forward Earnings ratio, CME is valued a bit more expensive than the industry average as 60.08% of the companies are valued more cheaply.
- CME is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.30, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.46 | ||
| Fwd PE | 23.7 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CME is valued cheaply inside the industry as 87.39% of the companies are valued more expensively.
- 60.08% of the companies in the same industry are more expensive than CME, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.64 | ||
| EV/EBITDA | 10.83 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.55
PEG (5Y)2.97
EPS Next 2Y7.13%
EPS Next 3Y6.89%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.83%, CME has a reasonable but not impressive dividend return.
- CME's Dividend Yield is slightly below the industry average, which is at 6.12.
- CME's Dividend Yield is comparable with the S&P500 average which is at 1.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.83% |
5.2 History
- On average, the dividend of CME grows each year by 16.00%, which is quite nice.
- CME has paid a dividend for at least 10 years, which is a reliable track record.
- CME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
5.3 Sustainability
- CME pays out 104.85% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of CME is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
279.07
-0.84 (-0.3%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners91.62%
Inst Owner Change-0.15%
Ins Owners0.24%
Ins Owner Change-0.44%
Market Cap100.63B
Revenue(TTM)11.29B
Net Income(TTM)3.72B
Analysts70
Price Target293.33 (5.11%)
Short Float %1.39%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.83% |
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)1.47%
PT rev (3m)0.39%
EPS NQ rev (1m)0.38%
EPS NQ rev (3m)2.58%
EPS NY rev (1m)0.47%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)1.59%
Revenue NQ rev (3m)3.49%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.46 | ||
| Fwd PE | 23.7 | ||
| P/S | 8.91 | ||
| P/FCF | 24.64 | ||
| P/OCF | 24.18 | ||
| P/B | 3.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.83 |
EPS(TTM)10.96
EY3.93%
EPS(NY)11.77
Fwd EY4.22%
FCF(TTM)11.33
FCFY4.06%
OCF(TTM)11.54
OCFY4.13%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)2.55
PEG (5Y)2.97
Graham Number138.85
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROCE | 24.11% | ||
| ROIC | 18.72% | ||
| ROICexc | 20.09% | ||
| ROICexgc | 151.85% | ||
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A | ||
| FCFM | 36.16% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexgc growth 3Y53.64%
ROICexgc growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 23.26% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 66.76 | ||
| Cash Conversion | 44.34% | ||
| Profit Quality | 109.88% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | N/A |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
Revenue Next Year6.53%
Revenue Next 2Y5.68%
Revenue Next 3Y5.64%
Revenue Next 5Y4.71%
EBIT growth 1Y12.23%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year12.32%
EBIT Next 3Y7.91%
EBIT Next 5Y7.1%
FCF growth 1Y23.34%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y22.71%
OCF growth 3Y15.38%
OCF growth 5Y6.67%
CME GROUP INC / CME FAQ
What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CME.
What is the valuation status of CME GROUP INC (CME) stock?
ChartMill assigns a valuation rating of 3 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.
Can you provide the profitability details for CME GROUP INC?
CME GROUP INC (CME) has a profitability rating of 7 / 10.
What is the earnings growth outlook for CME GROUP INC?
The Earnings per Share (EPS) of CME GROUP INC (CME) is expected to grow by 9.98% in the next year.
Can you provide the dividend sustainability for CME stock?
The dividend rating of CME GROUP INC (CME) is 4 / 10 and the dividend payout ratio is 104.85%.